| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-GABA-OH targets peptide synthesis and bioconjugation applications. As a GABA derivative, it serves as a linker for introducing γ-aminobutyric acid spacers into peptides and PROTAC molecules. The Fmoc group enables standard Fmoc-based SPPS. It does not have a specific biological receptor target but is used as a biochemical reagent for biomedical research.
|
|---|---|
| ln Vitro |
In conjugate applications such as PROTAC synthesis, fmoc-4-aminobutyric acid can serve as a PROTAC linker. Alkane terminator Fmoc-4-aminobutyric acid has amino groups and an amine that are protected by Fmoc. Under simple circumstances, the Fmoc group can be deprotected, and the bond can then be utilized to further conjugate the radical amine. When an activator like EDC or HATU is present, aminoamino compounds can react with primary amine groups to produce stable amide bonds.
In vitro activity of Fmoc-GABA-OH is primarily as a peptide synthesis reagent and PROTAC linker. As a biochemical compound, it can be used as a biomaterial or organic/chemical reagent for biomedical research. Fmoc-GABA-OH itself is not directly biologically active. Its utility is in preparing GABA-containing peptides and PROTAC molecules. |
| ln Vivo |
There is no specific in vivo activity data for Fmoc-GABA-OH as a standalone compound. Peptides and PROTACs containing GABA linkers synthesized using this building block may be evaluated in vivo for therapeutic applications. GABA linkers can provide flexibility and appropriate spacing in bifunctional molecules. Animal studies would be performed on the final peptide or PROTAC products.
|
| Enzyme Assay |
In vitro SPPS protocols for Fmoc-GABA-OH involve standard Fmoc chemistry. The compound is activated with coupling reagents such as HATU or HBTU (1 equiv) and DIPEA (2 equiv) in DMF, then coupled to resin-bound peptides. Fmoc deprotection uses 20% piperidine in DMF. Purity is ≥97% by HPLC. Coupling efficiency is monitored by HPLC or Kaiser test. Melting point is 172.0 to 176.0°C.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-GABA-OH as it is a synthesis building block. GABA-containing peptides or PROTACs synthesized using this reagent can be tested in cell culture. Compounds are dissolved in DMSO or appropriate buffers, sterile-filtered, and added to cells at concentrations of 0.1-100 µM. Incubation is typically 24-72 hours. Assays include cell viability, proliferation, and specific signaling readouts.
|
| Animal Protocol |
Animal studies with Fmoc-GABA-OH are not conducted directly. Peptides or PROTACs containing GABA linkers synthesized using this building block may be evaluated in vivo. Protocols involve administration of the compound via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs. GABA linkers can provide flexibility and influence the pharmacokinetics of bifunctional molecules.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-GABA-OH as a standalone compound is not applicable. The compound has molecular weight 325.36 g/mol, formula C₁₉H₁₉NO₄, and melting point 172.0 to 176.0°C. Storage: refrigerated (0-10°C). The Fmoc group is removed under basic conditions during peptide synthesis. The resulting GABA linker provides flexibility in peptide and PROTAC structures.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-GABA-OH is limited. The compound is for research use only. Standard safety precautions should be observed. Acute toxicity is expected to be low. Store refrigerated at 0-10°C. Proper personal protective equipment should be worn when handling. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| Additional Infomation |
Fmoc-GABA-OH (CAS#: 116821-47-7) is also known as Fmoc-γ-aminobutyric acid, Fmoc-4-aminobutanoic acid, N-Fmoc-4-aminobutyric acid, and 4-(Fmoc-amino)butyric acid. Its molecular formula is C₁₉H₁₉NO₄ and molecular weight is 325.36 g/mol. It is used as a building block in SPPS and as a linker in bioconjugation and PROTAC synthesis. It has no approved therapeutic indications.
|
| Molecular Formula |
C19H19NO4
|
|---|---|
| Molecular Weight |
325.35846
|
| Exact Mass |
325.131
|
| Elemental Analysis |
C, 70.14; H, 5.89; N, 4.31; O, 19.67
|
| CAS # |
116821-47-7
|
| PubChem CID |
2756086
|
| Appearance |
White to off-white powder
|
| Density |
1.256g/cm3
|
| Boiling Point |
571.9ºC at 760mmHg
|
| Melting Point |
174 °C
|
| Flash Point |
299.7ºC
|
| Vapour Pressure |
6.43E-14mmHg at 25°C
|
| Index of Refraction |
1.6
|
| LogP |
3.78
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
431
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)CCCNC(OCC1C2=CC=CC=C2C3=CC=CC=C31)=O
|
| InChi Key |
ACUIFAAXWDLLTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H19NO4/c21-18(22)10-5-11-20-19(23)24-12-17-15-8-3-1-6-13(15)14-7-2-4-9-16(14)17/h1-4,6-9,17H,5,10-12H2,(H,20,23)(H,21,22)
|
| Chemical Name |
4-(9H-fluoren-9-ylmethoxycarbonylamino)butanoic acid
|
| Synonyms |
Fmoc-4-aminobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0735 mL | 15.3676 mL | 30.7352 mL | |
| 5 mM | 0.6147 mL | 3.0735 mL | 6.1470 mL | |
| 10 mM | 0.3074 mL | 1.5368 mL | 3.0735 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
